PRQR - プロキュ―ア―ル・セラピュ―ティクス （ProQR Therapeutics N.V.） プロキュ―ア―ル・セラピュ―ティクスPRQRのチャート
PRQRの企業情報
| symbol | PRQR |
|---|---|
| 会社名 | ProQR Therapeutics N.V. （プロキュ―ア―ル・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ProQR Therapeutics N.V. (ProQR) formerly ProQR Therapeutics B.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA or Messenger Ribonucleic Acid (mRNA) that is transcribed from a mutated gene in order to restore the expression and function of normal or wild-type protein. Its product candidates include QR-010 an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF) QR-110 an oligonucleotide for the treatment of Leber’s congenital amaurosis (LCA) and QR-313 for the treatment of dystrophic epidermolysis bullosa (DEB). プロキュ―ア―ル・セラピュ―ティクスは、深刻な遺伝子疾患の治療や開発を行うオランダのバイオ医薬品企業。欠陥のあるメッセンジャ―RNAを特異的に標的・修復する治療候補を設計する。全世界に7万から10万の患者がいる嚢胞性線維症の治療のための病態修飾療法の開発に焦点を当てる。 proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: www.proqr.com |
| 本社所在地 | Zernikedreef 9 Leiden 2333 CK NLD |
| 代表者氏名 | Daniel De Boer ダニエル・デ・ボア |
| 代表者役職名 | Founding Chief Executive Officer |
| 電話番号 | +31 854-89-4932 |
| 設立年月日 | 40940 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 130人 |
| url | www.proqr-tx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/prqr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -42.47853 |
| 終値（lastsale） | 17.75 |
| 時価総額（marketcap） | 566839789 |
| 時価総額 | 時価総額（百万ドル） 725.42930 |
| 売上高 | 売上高（百万ドル） 2.65606 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 696.71117 |
| 当期純利益 | 当期純利益（百万ドル） -45.83228 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ProQR Therapeutics NV revenues increased from EUR658K to EUR1.5M. Net loss decreased 18% to EUR18M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development costs decrease of 12% to EUR13.7M (expense) Finance income and expense decrease of 66% to EUR590K (expense). |
PRQRのテクニカル分析
PRQRのニュース
Citi maintains ProQR Therapeutics NV at ''neutral'' with a price target of $2.10 2023/05/26 10:24:58 Investing.com
https://www.investing.com/news/pro/proqr-thera-receives-investment-bank-analyst-rating-update-3091869
Cantor Fitzgerald maintains ProQR Therapeutics NV at ''overweight'' with a price target of $4.50 2023/05/17 10:34:40 Investing.com
https://www.investing.com/news/pro/proqr-thera-receives-investment-bank-analyst-rating-update-3084563
Leber Congenital Amaurosis Market to Expand at a Significant Growth Rate During the Forecast Period (2022-32) - Estimates DelveInsight | ProQR Therapeutics, IVERIC bio, MeiraGTx, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies 2023/04/26 19:18:56 OpenPR
As per DelveInsight, the Leber Congenital Amaurosis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Leber congenital amaurosis patients in the 7MM and the launch of new therapies in the market.
Why Shares of ProQR Therapeutics Dropped on Wednesday 2023/03/29 16:30:55 The Motley Fool
The clinical-stage biotech released fourth-quarter and full-year earnings.
Kodiak, Arcturus top healthcare gainers; ProQR, Sharecare among losers 2023/03/29 14:05:07 Seeking Alpha
Kodiak Sciences (KOD) +19%. Arcturus Therapeutics (ARCT) +16%. ProQR Therapeutics (PRQR) -31%. Sharecare (SHCR) -29%.
Leber Congenital Amaurosis Market to Expand at a Significant Growth Rate During the Forecast Period (2022-32) - Estimates DelveInsight | ProQR Therapeutics, IVERIC bio, MeiraGTx, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies 2023/04/26 19:18:56 OpenPR
As per DelveInsight, the Leber Congenital Amaurosis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Leber congenital amaurosis patients in the 7MM and the launch of new therapies in the market.
Why Shares of ProQR Therapeutics Dropped on Wednesday 2023/03/29 16:30:55 The Motley Fool
The clinical-stage biotech released fourth-quarter and full-year earnings.
Kodiak, Arcturus top healthcare gainers; ProQR, Sharecare among losers 2023/03/29 14:05:07 Seeking Alpha
Kodiak Sciences (KOD) +19%. Arcturus Therapeutics (ARCT) +16%. ProQR Therapeutics (PRQR) -31%. Sharecare (SHCR) -29%.
Earnings Outlook For ProQR Therapeutics 2023/03/28 14:02:48 Benzinga
ProQR Therapeutics (NASDAQ: PRQR ) is set to give its latest quarterly earnings report on Wednesday, 2023-03-29. Here''s what investors need to know before the announcement. Analysts estimate that ProQR Therapeutics will report an earnings per share (EPS) of $-0.18. ProQR Therapeutics bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Currently -31.25% Below Its 52-Week High But The Downside Potential May Surprise You 2023/03/10 17:00:00 Marketing Sentinel
In recent trading session, ProQR Therapeutics N.V. (NASDAQ:PRQR) saw 0.25 million shares changing hands at last check today with its beta currently measuring 0.09. Company’s recent per share price level of $2.88 trading at -$0.3 or -9.43% at last check today assigns it a market valuation of $219.48M. That most recent trading price of PRQR’s … ProQR Therapeutics N.V. (NASDAQ:PRQR) Currently -31.25% Below Its 52-Week High But The Downside Potential May Surprise You Read More »
How should investors view ProQR Therapeutics N.V. (PRQR)? 2023/01/03 13:48:00 US Post News
A share of ProQR Therapeutics N.V. (NASDAQ:PRQR) closed at $3.70 per share on Friday, up from $3.37 day before. While ProQR Therapeutics N.V. has overperformed by 9.79%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -54.71%, with highs and lows ranging from $8.60 […]
A stock that deserves closer examination: ProQR Therapeutics N.V. (PRQR) 2022/12/27 13:16:00 US Post News
ProQR Therapeutics N.V. (NASDAQ:PRQR) closed Friday at $2.71 per share, up from $2.70 a day earlier. While ProQR Therapeutics N.V. has overperformed by 0.37%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRQR fell by -66.95%, with highs and lows ranging from $8.60 to $0.53, whereas […]
ProQR Therapeutics N.V. (NASDAQ: PRQR) Stock Forecast: Bullish Signals Pointing To $5.00 In 2022 2022/12/27 12:30:00 Marketing Sentinel
In the last trading session, 5.55 million shares of the ProQR Therapeutics N.V. (NASDAQ:PRQR) were traded, and its beta was 0.48. Most recently the company’s share price was $2.71, and it changed around $0.01 or 0.37% from the last close, which brings the market valuation of the company to $192.90M. PRQR currently trades at a … ProQR Therapeutics N.V. (NASDAQ: PRQR) Stock Forecast: Bullish Signals Pointing To $5.00 In 2022 Read More »